Abstract
Abstract
Aims/hypothesis
The aim of this study was to determine the applicability of dual activation of glucagon-like peptide-1 (GLP-1) and apelin (APJ) receptors as a next-generation therapeutic option for obesity and diabetes.
Methods
A fully characterised unimolecular dual GLP-1/APJ receptor agonist, namely exendin–linker–apelin (ELA), as well as its acylated long-acting equivalent, ELA-Lys
12
(γGluPal), were administered once daily to high-fat-fed (HFF) mice for 28 days, with liraglutide used as a positive control. Effects on appetite and body weight, as well as glucose, pyruvate and insulin tolerance, circulating lipids, liver transaminases and triglyceride content, indirect calorimetry measurements and pancreatic morphology were then examined.
Results
ELA, and particularly ELA-Lys
12
(γGluPal), reduced food intake, circulating glucose and HbA
1c
concentrations relative to saline-treated HFF control mice. ELA-Lys
12
(γGluPal) substantially reduced blood glucose concentrations during glucose and pyruvate tolerance tests. These positive effects were largely independent of alterations in circulating insulin. However, circulating triglyceride and LDL-cholesterol concentrations were lowered, accompanied by complete normalisation of hepatic triglyceride and aminotransferase levels in all GLP-1/apelin hybrid-treated HFF mice. Assessment of indirect calorimetry demonstrated restoration of metabolic flexibility in mice treated with ELA-Lys
12
(γGluPal), despite reductions in energy expenditure. Notably, GLP-1/apelin hybrid treatment did not affect locomotor activity, whereas liraglutide treatment was associated with marked reductions in physical activity. Histological assessment of pancreatic islets revealed that all treatment modalities induced a marked enhancement of beta cell proliferative frequency, and accompanying suppression of apoptotic rates, without major alterations in islet or beta cell areas.
Conclusions/interpretation
Chronic administration of ELA, and especially ELA-Lys
12
(γGluPal), delivered pronounced metabolic improvements in HFF mice, with the clearest differences from liraglutide treatment evident in circulating lipids and hepatic biomarkers.